Reforms to the post-market monitoring of medicines and medical devices are being implemented in response to the recommendations arising from the Review of Medicines and Medical Devices Regulation.
The reforms will enhance monitoring and compliance of therapeutic products that are released to market.
Reforms that have been implemented
Introduction of the Pharmacovigilance Inspection Program to ensure medicine sponsors are meeting their pharmacovigilance and risk management requirements.
The Black Triangle Scheme has been introduced to provide a way for practitioners and patients to identify certain new prescription medicines and encourage reporting of associated adverse events.
The creation of a new electronic adverse events reporting system for medicines that allows efficient reporting of adverse events.
Changes to the format of the product information document to allow for the most important clinical information about a medicine to be upfront and easily accessible.